NeuBase Therapeutics (NeuBase Therapeutics) Inventory-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. NeuBase Therapeutics's Average Total Inventories for the quarter that ended in Sep. 2023 was $0.00 Mil. NeuBase Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

NeuBase Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2023 stayed the same from Jun. 2023 (0.00) to Jun. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

NeuBase Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for NeuBase Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Inventory-to-Revenue Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Inventory-to-Revenue

Get a 7-Day Free Trial

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NeuBase Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, NeuBase Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuBase Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Inventory-to-Revenue falls into.

NeuBase Therapeutics Inventory-to-Revenue Calculation

NeuBase Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Sep. 2021 is calculated as

	Inventory-to-Revenue (A: Sep. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Sep. 2020 )	+	Total Inventories (A: Sep. 2021 ))	/	count )	/	Revenue (A: Sep. 2021 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

NeuBase Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

	Inventory-to-Revenue (Q: Sep. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2023 )	+	Total Inventories (Q: Sep. 2023 ))	/	count )	/	Revenue (Q: Sep. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

NeuBase Therapeutics (NAS:NBSE) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

NeuBase Therapeutics's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2023 )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

NeuBase Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2023 )	/	Average Total Inventories (Q: Sep. 2023 )
	=	0	/	0
	=

NeuBase Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

O7P:Germany O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Executives

Symetryx Corp	10 percent owner	2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann	officer: COO	700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei	officer: See Remarks	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall	director	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles	director	2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast	director
Dietrich A Stephan	director, 10 percent owner, officer: President and CEO	213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc	10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801